Ganaxolone Amorphous Solid Dispersion for Solubility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Ganaxolone, a neurosteroid used for treating epilepsy and other central nervous system disorders, poses challenges due to its poor solubility and variability in blood levels upon oral administration, leading to ineffective dosage forms and significant side effects.
Innovation Solution
Development of stable ganaxolone solid oral dosage forms incorporating small molecule complexing agents and ionic dispersion modulators to enhance stability, bioavailability, and pharmacokinetic properties, including pulsatile release formulations to manage side effects and improve patient compliance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ganaxolone is administered orally in conventional dosage forms, then it can be delivered to patients, but it exhibits poor solubility and high variability in blood levels leading to ineffective treatment and significant side effects
Solution Approach 1:
The patent transforms ganaxolone from a crystalline solid to an amorphous solid dispersion, fundamentally changing its physical state and dissolution behavior. This parameter change enables the poorly soluble neurosteroid to achieve rapid and complete dissolution in the gastrointestinal tract, resulting in consistent and reliable blood level profiles without the high variability seen in conventional formulations.
Solution Approach 2:
The invention creates a composite material system where ganaxolone is dispersed within a polymer matrix (such as HPMC or HPC). This composite structure maintains ganaxolone in an amorphous state while providing a controlled release mechanism, thereby achieving both improved solubility and consistent pharmacokinetics that eliminate the reliability issues of conventional formulations.
2Ease of operation
If conventional ganaxolone formulations are used, then administration is simple, but peak plasma concentrations cause significant side effects
Solution Approach 1:
The amorphous solid dispersion formulation creates a pulsatile release pattern where ganaxolone is delivered in controlled bursts rather than as a single peak. This periodic action profile maintains therapeutic levels while avoiding the high peak concentrations that cause side effects, all while preserving the simplicity of oral administration.
Solution Approach 2:
The formulation dynamically adjusts drug release based on gastrointestinal conditions. The amorphous polymer matrix responds to changes in pH, moisture, and mechanical stress along the GI tract, modulating the release rate to prevent excessive peak concentrations while maintaining ease of oral administration.
3Reliability
If ganaxolone is formulated to improve solubility, then bioavailability increases, but formulation complexity increases
Solution Approach 1:
The patent uses hydrophilic polymers (HPMC, HPC) as intermediary materials that facilitate the dissolution of ganaxolone. These polymer mediators create a solubilizing environment that allows the poorly soluble neurosteroid to achieve high bioavailability through a relatively simple solid dispersion process, avoiding the need for complex delivery systems.
Data Source
AI summary
In certain embodiments, the invention is directed to composition comprising stable particles comprising ganaxolone, wherein the volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm.